AG
TSHA icon

Artal Group’s Taysha Gene Therapies TSHA Stock Holding History

Artal Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,354,214
Closed -$9.75M – 92
2024
Q2 		$9.75M Buy
4,354,214
+666,666
+18% +$1.94M 0.25% 40
2024
Q1 		$10.6M Buy
3,687,548
+24,444
+0.7% +$50.9K 0.27% 44
2023
Q4 		$6.48M Hold
3,663,104
– – 0.22% 43
2023
Q3 		$11.6M Buy
3,663,104
+2,222,222
+154% +$4.15M 0.5% 32
2023
Q2 		$952K Hold
1,440,882
– – 0.03% 94
2023
Q1 		$1.15M Hold
1,440,882
– – 0.07% 92
2022
Q4 		$3.26M Buy
1,440,882
+400,000
+38% +$810K 0.18% 74
2022
Q3 		$2.01M Hold
1,040,882
– – 0.09% 95
2022
Q2 		$3.87M Hold
1,040,882
– – 0.21% 66
2022
Q1 		$6.79M Hold
1,040,882
– – 0.28% 68
2021
Q4 		$12.1M Hold
1,040,882
– – 0.33% 62
2021
Q3 		$19.4M Hold
1,040,882
– – 0.43% 55
2021
Q2 		$22.1M Hold
1,040,882
– – 0.45% 49
2021
Q1 		$21.1M Hold
1,040,882
– – 0.37% 61
2020
Q4 		$27.6M Sell
1,040,882
-100,000
-9% -$2.15M 0.59% 44
2020
Q3 		$25.6M Buy
+1,140,882
New +$26.8M 0.62% 38

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Artal Group's TSHA Position: Q3 2024 in Review

Artal Group sold out of Taysha Gene Therapies (TSHA) in Q3 2024, closing a stake of 4,354,214 shares — an estimated $9.75M sold.

Artal Group first reported a position in TSHA in Q3 2020 and held it in 16 quarters. The position peaked at $27.6M in Q4 2020. 119 funds tracked by Wall St. Rank hold TSHA as of Q3 2024.

  • Artal Group reported no remaining Taysha Gene Therapies position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 4,354,214 Taysha Gene Therapies shares in Q3 2024, an estimated $9.75M.
  • Artal Group first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 16 quarters.
  • Artal Group's Taysha Gene Therapies position peaked at $27.6M in Q4 2020.
  • 119 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.